This work demonstrates that although the chemokine crosstalk in the tumor microenvironment (TME) is a complex and overall poorly understood process, both the CCL2:CCR2 and CCL5:CCR5 ligand/receptor pairs have been identified as likely therapeutic targets across several types of cancers. The gene discussed is CCL5; the disease is neoplasm.